Cargando…

New findings on primary and acquired resistance to anti-EGFR therapy in metastatic colorectal cancer: do all roads lead to RAS?

Anti-epidermal growth factor receptor therapy with the monoclonal antibodies cetuximab and panitumumab is the main targeted treatment to combine with standard chemotherapy for metastatic colorectal cancer. Many clinical studies have shown the benefit of the addition of these agents for patients with...

Descripción completa

Detalles Bibliográficos
Autores principales: Bronte, Giuseppe, Silvestris, Nicola, Castiglia, Marta, Galvano, Antonio, Passiglia, Francesco, Sortino, Giovanni, Cicero, Giuseppe, Rolfo, Christian, Peeters, Marc, Bazan, Viviana, Fanale, Daniele, Giordano, Antonio, Russo, Antonio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4694794/
https://www.ncbi.nlm.nih.gov/pubmed/26318427
_version_ 1782407523877257216
author Bronte, Giuseppe
Silvestris, Nicola
Castiglia, Marta
Galvano, Antonio
Passiglia, Francesco
Sortino, Giovanni
Cicero, Giuseppe
Rolfo, Christian
Peeters, Marc
Bazan, Viviana
Fanale, Daniele
Giordano, Antonio
Russo, Antonio
author_facet Bronte, Giuseppe
Silvestris, Nicola
Castiglia, Marta
Galvano, Antonio
Passiglia, Francesco
Sortino, Giovanni
Cicero, Giuseppe
Rolfo, Christian
Peeters, Marc
Bazan, Viviana
Fanale, Daniele
Giordano, Antonio
Russo, Antonio
author_sort Bronte, Giuseppe
collection PubMed
description Anti-epidermal growth factor receptor therapy with the monoclonal antibodies cetuximab and panitumumab is the main targeted treatment to combine with standard chemotherapy for metastatic colorectal cancer. Many clinical studies have shown the benefit of the addition of these agents for patients without mutations in the EGFR pathway. Many biomarkers, including KRAS and NRAS mutations, BRAF mutations, PIK3CA mutations, PTEN loss, AREG and EREG expression, and HER-2 amplification have already been identified to select responders to anti-EGFR agents. Among these alterations KRAS and NRAS mutations are currently recognized as the best predictive factors for primary resistance. Liquid biopsy, which helps to isolate circulating tumor DNA, is an innovative method to study both primary and acquired resistance to anti-EGFR monoclonal antibodies. However, high-sensitivity techniques should be used to enable the identification of a wide set of gene mutations related to resistance.
format Online
Article
Text
id pubmed-4694794
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-46947942016-01-20 New findings on primary and acquired resistance to anti-EGFR therapy in metastatic colorectal cancer: do all roads lead to RAS? Bronte, Giuseppe Silvestris, Nicola Castiglia, Marta Galvano, Antonio Passiglia, Francesco Sortino, Giovanni Cicero, Giuseppe Rolfo, Christian Peeters, Marc Bazan, Viviana Fanale, Daniele Giordano, Antonio Russo, Antonio Oncotarget Review Anti-epidermal growth factor receptor therapy with the monoclonal antibodies cetuximab and panitumumab is the main targeted treatment to combine with standard chemotherapy for metastatic colorectal cancer. Many clinical studies have shown the benefit of the addition of these agents for patients without mutations in the EGFR pathway. Many biomarkers, including KRAS and NRAS mutations, BRAF mutations, PIK3CA mutations, PTEN loss, AREG and EREG expression, and HER-2 amplification have already been identified to select responders to anti-EGFR agents. Among these alterations KRAS and NRAS mutations are currently recognized as the best predictive factors for primary resistance. Liquid biopsy, which helps to isolate circulating tumor DNA, is an innovative method to study both primary and acquired resistance to anti-EGFR monoclonal antibodies. However, high-sensitivity techniques should be used to enable the identification of a wide set of gene mutations related to resistance. Impact Journals LLC 2015-07-22 /pmc/articles/PMC4694794/ /pubmed/26318427 Text en Copyright: © 2015 Bronte et al. http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Review
Bronte, Giuseppe
Silvestris, Nicola
Castiglia, Marta
Galvano, Antonio
Passiglia, Francesco
Sortino, Giovanni
Cicero, Giuseppe
Rolfo, Christian
Peeters, Marc
Bazan, Viviana
Fanale, Daniele
Giordano, Antonio
Russo, Antonio
New findings on primary and acquired resistance to anti-EGFR therapy in metastatic colorectal cancer: do all roads lead to RAS?
title New findings on primary and acquired resistance to anti-EGFR therapy in metastatic colorectal cancer: do all roads lead to RAS?
title_full New findings on primary and acquired resistance to anti-EGFR therapy in metastatic colorectal cancer: do all roads lead to RAS?
title_fullStr New findings on primary and acquired resistance to anti-EGFR therapy in metastatic colorectal cancer: do all roads lead to RAS?
title_full_unstemmed New findings on primary and acquired resistance to anti-EGFR therapy in metastatic colorectal cancer: do all roads lead to RAS?
title_short New findings on primary and acquired resistance to anti-EGFR therapy in metastatic colorectal cancer: do all roads lead to RAS?
title_sort new findings on primary and acquired resistance to anti-egfr therapy in metastatic colorectal cancer: do all roads lead to ras?
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4694794/
https://www.ncbi.nlm.nih.gov/pubmed/26318427
work_keys_str_mv AT brontegiuseppe newfindingsonprimaryandacquiredresistancetoantiegfrtherapyinmetastaticcolorectalcancerdoallroadsleadtoras
AT silvestrisnicola newfindingsonprimaryandacquiredresistancetoantiegfrtherapyinmetastaticcolorectalcancerdoallroadsleadtoras
AT castigliamarta newfindingsonprimaryandacquiredresistancetoantiegfrtherapyinmetastaticcolorectalcancerdoallroadsleadtoras
AT galvanoantonio newfindingsonprimaryandacquiredresistancetoantiegfrtherapyinmetastaticcolorectalcancerdoallroadsleadtoras
AT passigliafrancesco newfindingsonprimaryandacquiredresistancetoantiegfrtherapyinmetastaticcolorectalcancerdoallroadsleadtoras
AT sortinogiovanni newfindingsonprimaryandacquiredresistancetoantiegfrtherapyinmetastaticcolorectalcancerdoallroadsleadtoras
AT cicerogiuseppe newfindingsonprimaryandacquiredresistancetoantiegfrtherapyinmetastaticcolorectalcancerdoallroadsleadtoras
AT rolfochristian newfindingsonprimaryandacquiredresistancetoantiegfrtherapyinmetastaticcolorectalcancerdoallroadsleadtoras
AT peetersmarc newfindingsonprimaryandacquiredresistancetoantiegfrtherapyinmetastaticcolorectalcancerdoallroadsleadtoras
AT bazanviviana newfindingsonprimaryandacquiredresistancetoantiegfrtherapyinmetastaticcolorectalcancerdoallroadsleadtoras
AT fanaledaniele newfindingsonprimaryandacquiredresistancetoantiegfrtherapyinmetastaticcolorectalcancerdoallroadsleadtoras
AT giordanoantonio newfindingsonprimaryandacquiredresistancetoantiegfrtherapyinmetastaticcolorectalcancerdoallroadsleadtoras
AT russoantonio newfindingsonprimaryandacquiredresistancetoantiegfrtherapyinmetastaticcolorectalcancerdoallroadsleadtoras